Get started
JNJ - Potential Sell Opportunity at Resistance LevelNYSE:JNJ has reached a significant resistance zone, marked by prior price rejections and strong selling pressure. This area has historically acted as a key supply zone, indicating the potential for a pullback if sellers regain control. The current market structure suggests that if the price confirms a rejection from this resistance zone, there is a high likelihood of a downward move. I anticipate that if rejection occurs, the market may head lower toward the 155.00 level, which represents a logical target within the current market structure. This setup reflects the potential for a retracement after an impulsive move, supported by the confluence of previous price behavior and the current structure. If you agree with this analysis or have additional insights, feel free to share your thoughts in the comments!
NYSE:JNJShort
by DanieIM
3
Coca-Cola at Key Resistance: Will Sellers Step In?NYSE:KO has reached a significant supply zone, marked by prior price rejections and strong selling interest. This area has historically acted as a resistance level, suggesting the potential for a bearish reversal if sellers regain control. The recent bullish momentum has brought the price into this key resistance zone, and if the market confirms rejection here, we could see a move lower. I anticipate that if sellers step in, the price may decline toward the 68.80 level. This setup reflects the potential for a retracement after an impulsive move, supported by the confluence of previous price behavior and the current structure. If you agree with this analysis or have any additional thoughts, feel free to share them in the comments!
NYSE:KOShort
by DanieIM
Berkshire Hathaway - Gearing Up for a Bullish RallyNYSE:BRK.B is exhibiting strong bullish momentum, supported by consistent price strength and a clear uptrend. Recent price action confirms buyers' dominance, with the stock pushing higher and breaking through key levels, signaling further upside potential. With no significant resistance ahead, the next logical target is $519.50, aligning with the upper boundary of the channel. If you agree with this analysis or have additional insights, feel free to share your thoughts in the comments!
NYSE:BRK.BLong
by DanieIM
MERCADOLIBRE ($MELI) SOARS IN Q4—E-COMMERCE & FINTECH SHINE MERCADOLIBRE ( NASDAQ:MELI ) SOARS IN Q4—E-COMMERCE & FINTECH SHINE (1/9) Good evening, Tradingview! MercadoLibre ( NASDAQ:MELI ) is sizzling—Q4 revenue up 37%, a $ 6.1B haul 📈🔥. Fintech and e-commerce fuel a 33% surge—let’s unpack this Latin dynamo! 🚀 (2/9) – REVENUE RUSH • Q4 Take: $ 6.1B—37% leap, tops $ 5.9B est. 💥 • EPS: $ 12.61—blasts past $ 7.94 hopes 📊 • Net Income: $ 639M—beats $ 402M dreams NASDAQ:MELI ’s humming—growth’s got zing! (3/9) – BIG MOVES • GMV: $ 14.5B—56% jump FX-neutral 🌍 • Payments: $ 58.9B TPV—49% up 🚗 • Credit Boom: $ 6.6B—74% growth 🌟 NASDAQ:MELI ’s flexing muscle—full throttle! (4/9) – MARKET VIBE • P/E: ~60—above Amazon’s 40, PDD’s 20 📈 • Growth: 37% smokes peers’ 10% • Targets: 2,400−3,000—10-38% upside 🌍 Premium price—worth the juice? (5/9) – RISKS ON DECK • FX Woes: Brazil, Mexico currencies wobble ⚠️ • Comp: Amazon, locals eye the prize 🏛️ • Rates: $ 6.6B credit—defaults lurk? 📉 Hot run—can it dodge the heat? (6/9) – SWOT: STRENGTHS • E-comm: $ 14.5B GMV—LatAm king 🌟 • Fintech: $ 58.9B TPV—Pago’s gold 🔍 • Logistics: 6 new centers—zippy edge 🚦📉 NASDAQ:MELI ’s a double-threat dynamo! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: High P/E, FX swings 💸 • Opportunities: Ad bucks, untapped markets 🌍 Can NASDAQ:MELI zap past the bumps? (8/9) – NASDAQ:MELI ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—$ 3,000 in sight. 2️⃣ Neutral—Growth’s hot, risks hover. 3️⃣ Bearish—FX bites back. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:MELI ’s $ 6.1B Q4 and fintech flex spark buzz—$ 14.5B GMV shines 🌍🪙. High P/E, but growth rules—champ or chase?
NASDAQ:MELI
by DCAChampion
Aggressive growth stock - Buy the dip?For those looking to diversify their portfolio this aggressive growth stock selling fresh pet food is a great choice. I traded the bounce at the 200W moving average and golden Fibonacci retracement confluence. The bounce was strong and the trade was executed at $100. Looking at the fundamentals we are talking about over 20% revenue growth quarter over quarter. Pet owners are constantly seeking out good quality food for their animals, this company ticks a lot of boxes. I’ll exit the trade if we drop $100. Not financial advice, always do what’s best for you.
NASDAQ:FRPTLong
by NoFOMO_
2
MVIS Swing Trade Setup & Technical AnalysisCurrent Price Action: • MVIS is trading at a key support zone ($1.30-$1.40), which has historically been an accumulation area. • The broader trend remains bullish, but short-term price action is consolidating. • Volume is increasing, indicating growing interest, but a decisive breakout or rejection from this level will determine the next move. Potential Scenarios: • Bullish Case: If a bounce is confirmed, the first resistance to test is $1.80-$2.00, with potential continuation toward $2.50 and beyond. • Bearish Case: If support breaks, the next downside targets are $1.00 and possibly lower. Trade Plan: Stop-Loss & Take-Profit Levels • Entry Zone: $1.30 - $1.40 • Stop-Loss: Below $1.20 (or tighter at $1.25 to limit risk) • First Take-Profit (TP1): $1.80 - $2.00 (key resistance zone) • Second Take-Profit (TP2): $2.50 (strong resistance area) • Trailing Stop: If the price reaches 20% profit, set a trailing stop to protect gains. Upcoming Catalyst: • Earnings in 9 days – Could drive volatility and momentum. • Analyst Price Target: Average estimate of $2.50, indicating potential upside. ________________________________________ Key Partnerships & Clients • Stellantis – Confirmed partnership to integrate MVIS LIDAR into next-generation vehicle safety and automation. • Ibeo Acquisition – Strengthened MVIS’s LIDAR portfolio by acquiring key assets from Ibeo Automotive Systems. • NDA Clients – MVIS has disclosed working with multiple OEMs in the automotive sector, though specific names remain confidential. • Defense & Industrial Interest – Their sensors are being evaluated for military and industrial applications. Why It Matters • MVIS LIDAR aligns with the growing push for AI-driven automation and autonomous vehicles. • The Stellantis partnership validates real-world adoption of their technology. • As AI and automation expand, high-resolution LIDAR demand is expected to rise.
NASDAQ:MVISLong
by johnhhdoan
WATCH $LYV The upward trend is positiveFundamental Analysis Fundamental analysis focuses on the financial health, business model, and external market factors that influence a stock's value. Company Profile Live Nation Entertainment (LYV) is a global leader in live entertainment and ticket sales, with Ticketmaster as a subsidiary. It generates revenue through ticket sales, concert production, sponsorships, and merchandising. Financial Health Revenue Growth: Live Nation has shown strong revenue growth in recent years, driven by the resurgence of live events after COVID-19. Profitability: While the company has strong revenue, profitability can fluctuate due to operational costs and investments in new venues and technologies. Debt Load: LYV has a significant amount of debt, which could pose a risk in a rising interest rate environment. Competition & Market Position LYV holds a dominant market position in the live entertainment industry, benefiting from exclusive deals with artists and venues. However, regulatory scrutiny and antitrust investigations, particularly concerning Ticketmaster, could pose risks. External Factors Consumer trends (such as demand for live events) Economic conditions (inflation, recession risks) that could impact entertainment spending Technical Analysis Technical analysis focuses on price movements, trends, and indicators. Trend Analysis LYV has shown an upward trend in recent months but with fluctuations. The stock may be trading above or around the 200-day moving average (SMA200), which is a positive signal for long-term investors. Support & Resistance Levels Key support: Around $80 (if recently tested) Key resistance: Around $95-$100 (depending on previous peaks) Technical Indicators RSI (Relative Strength Index): Indicates whether the stock is overbought or oversold. An RSI above 70 suggests overbought conditions, while below 30 suggests oversold. MACD (Moving Average Convergence Divergence): A bullish crossover can signal a buying opportunity, while a bearish crossover may indicate a selling point. Conclusion Fundamental: LYV has strong growth prospects due to rising demand for live events, but its debt load and competitive pressures pose risks. Technical: The upward trend is positive, but resistance levels need to be broken for further growth. Monitoring technical indicators is crucial.
NYSE:LYV
by swingstocktraders
PLTR - Next Generational Company Palantir Technologies Inc. (NYSE: PLTR) is an American software company specializing in big data analytics. Palantir offers platforms like Palantir Gotham, used by defense and intelligence agencies; Palantir Foundry, designed for data integration and analysis across industries; and Palantir Apollo, which facilitates continuous software deployment. In April 2023, Palantir introduced the Artificial Intelligence Platform (AIP) to integrate large language models into secure networks. Recent earnings have surprised to the upside, reassuring investors that the company is able to monetize its services in an industry where many AI related and data analytic companies to not provide similar competitiveness. At the moment, Palantir has seen a massive drop from the all time high, creating a potential ABC corrective structure with the 1-1 extension being around the $80 range. I will be interesting in adding shares if Palantir can flush down to these levels in the coming days!
NASDAQ:PLTRLong
by afurs1
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion